Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Stopped the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

• DRUG: Panitumumab
• DRUG: Pemetrexed
• DRUG: Cisplatin

Sponsor

WiSP Wissenschaftlicher Service Pharma GmbH

Collaborators

• [object Object]